Clinical Trials Sponsored by Chugai Pharma USA

Total 326 results

Chugai Pharma USA

Completed

Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis

Gastroparesis

United States
Chugai Pharma USA

Completed

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

Atherosclerosis | Coronary Restenosis | Graft Occlusion, Vascular

United States
Chugai Pharma USA

Completed

An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer

Breast Cancer | Breast Neoplasms | Metastasis

United States
Memorial Sloan Kettering Cancer Center
Chugai Pharma USA

Recruiting

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

Primary Extra-cranial Solid Tumor | Recurrent or Refractory Glypican 3 (GPC3)

United States
Heinrich-Heine University, Duesseldorf
Chugai Pharma USA; Terumo BCT

Completed

Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia® (optiMaL)

Healthy Allogeneic Donors | Granulocyte Colony-stimulating Factor (G-CSF) Mobilized

Germany
Groupe Francais De Pneumo-Cancerologie
Sanofi; Chugai Pharma USA

Completed

Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

France
Chugai Pharma Taiwan

Completed

Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

Hemodialysis | Hyperphosphatemia | Cardiovascular Events
Chugai Pharma Taiwan

Completed

Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients

Rheumatoid Arthritis

Taiwan
Chugai Pharma Taiwan

Completed

Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients

Rheumatoid Arthritis (RA)

Taiwan
University of Liverpool
GlaxoSmithKline; Chugai Pharma USA; Napp Pharmaceuticals Limited

Unknown

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment (RIAltO)

Chronic Lymphocytic Leukaemia

United Kingdom
Chugai Pharma Europe Ltd.

Completed

Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors

Solid Tumors

United Kingdom
Chugai Pharma France
ITEC Services

Completed

Assessment of Giant Cell Arteritis Medical Practices in France (ARTEMIS)

Giant Cell Arteritis

France
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute; Chugai Pharma USA

Active, not recruiting

RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

Advanced Non-small Cell Lung Cancer

United States
Ruijin Hospital
Chugai Pharma China

Completed

Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts (ASRAB-Pilot)

Coronary Artery Bypass Graft | Radial Artery Grafts | Antispastic Therapy | Pilot Study

China
iOMEDICO AG
Chugai Pharma Europe Ltd.

Completed

Patient Reported Outcomes Registry in Patient With Cancer Cachexia (PROXie)

Metastatic Pancreatic Cancer | NSCLC, Metastatic

Germany
Institut Bergonié
Novartis; Chugai Pharma France

Recruiting

Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas (CIRSARC)

Resectable | Non-metastatic Soft-tissue Sarcoma

France
Teikoku Pharma USA, Inc.

Recruiting

Evaluation of the Dexmedetomidine Transdermal Systems for Postoperative Analgesia Following Abdominoplasty (DMT2111)

Pain, Postoperative

United States
Meiji Pharma USA Inc.

Completed

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

United States, Canada
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (OPTIC)

Thyroid Eye Disease | Graves' Orbitopathy

United States, Italy, Germany
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X)

Thyroid Eye Disease

Italy, United States, Germany
Teikoku Pharma USA, Inc.

Unknown

Evaluating Efficacy of the Dexmedetomidine Transdermal System for Postoperative Analgesia Following Abdominoplasty

Pain, Postoperative

United States
Fidia Pharma USA Inc.

Completed

2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)

Knee Osteoarthritis | Osteoarthritis, Knee | Patellofemoral Osteoarthritis

United States
Horizon Pharma USA, Inc.

Approved for marketing

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (EAP)

Thyroid Eye Disease | Graves' Orbitopathy

United States
Horizon Pharma USA, Inc.

Completed

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Cystinosis

France, United States, United Kingdom, Belgium, Italy, Netherlands
Horizon Pharma USA, Inc.

Completed

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Terminated

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Mitochondrial Diseases

United States
Horizon Pharma USA, Inc.

Completed

"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"

Cystic Fibrosis

United States
Horizon Pharma USA, Inc.

Completed

A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Horizon Pharma USA, Inc.

Completed

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Cystinosis

United States
Hoffmann-La Roche
Chugai Pharma Europe Ltd.

Completed

Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthritis in Everyday Clinical Practice (ARATA)

Rheumatoid Arthritis

Germany
Horizon Pharma USA, Inc.

Recruiting

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Thyroid Eye Disease

United States
Teikoku Pharma USA, Inc.

Completed

Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System (DTP-System)

Irritation/Irritant

United States
Horizon Pharma USA, Inc.

Completed

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Thyroid-Associated Ophthalmopathy | Thyroid Associated Ophthalmopathies

United Kingdom, United States, Germany, Italy
Horizon Pharma USA, Inc.

Completed

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

Cystic Fibrosis (CF)

Germany, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Horizon Pharma USA, Inc.

Completed

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (MITO-001)

Inherited Mitochondrial Disease, Including Leigh Syndrome

United States
Teikoku Pharma USA, Inc.

Completed

Flurbiprofen Tape for Treatment of Chronic Low Back Pain (LBP)

Chronic Low Back Pain

United States
Teikoku Pharma USA, Inc.

Completed

Study of a New Dressing for Use With Topical Medications

Psoriasis

United States
Teikoku Pharma USA, Inc.

Not yet recruiting

Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type

Agitation
Horizon Pharma USA, Inc.

Completed

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

Cystinosis

United States, Brazil
Horizon Pharma USA, Inc.

Completed

A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Horizon Pharma USA, Inc.

Completed

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

Aldehyde Dehydrogenase-2 (ALDH2) Deficiency

United States
Bioniche Pharma USA LLC

Completed

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

Myelodysplastic Syndrome

United States, France
Horizon Therapeutics USA, Inc.

Terminated

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis

United States
Astellas Pharma Inc
Ono Pharma USA Inc

Completed

A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation

Bone Diseases | Osteoporosis | Osteoporosis, Postmenopausal

Japan
Horizon Therapeutics USA, Inc.

Completed

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

Thyroid Eye Disease | Chronic (Inactive) Thyroid Eye Disease

United States
Xi'an Honghui Hospital
Chugai Pharma China Co., Ltd.

Recruiting

Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteoporosis.

Osteoporosis in Postmenopausal Women

China
Christoph Königs
Roche Pharma AG; Chugai Pharma Germany GmbH

Recruiting

Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab (NAVIGATE)

Severe Hemophilia A | Severe Hemophilia A With Inhibitor | Severe Hemophilia A Without Inhibitor

Germany
Shanghai Pharma Biotherapeutics USA Inc.

Recruiting

Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Liposarcoma, Dedifferentiated

United States

3

Subscribe